Ensysce Biosciences (ENSC) Interest Coverage Ratio (2020 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Interest Coverage Ratio of 587.39 for Q3 2025, down 470.16% year-over-year from 158.69 in Q3 2024, and down 6.03% quarter-over-quarter from 553.96 in Q2 2025.
Ensysce Biosciences (ENSC) Interest Coverage Ratio (2020 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Interest Coverage Ratio for 6 consecutive years, with 587.39 the latest figure, recorded in Q3 2025.
- In Q3 2025, Interest Coverage Ratio fell 470.16% year-over-year to 587.39; the TTM figure through Sep 2025 stood at 686.38 (down 13882.05% YoY), while the FY2024 annual figure was 5.25, up 16.71% from the prior year.
- Interest Coverage Ratio eased to 587.39 in Q3 2025 per ENSC's latest filing, from 553.96 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 158.69 in Q3 2024 and bottomed at 1710.91 in Q1 2023.
- Historically, Interest Coverage Ratio has averaged 408.49 across 5 years, with a median of 235.71 in 2022.
- Annual changes were most pronounced in 2022 — Interest Coverage Ratio slumped 1974420.04% — and 2024, when it jumped 144.83%.
- Ensysce Biosciences' Interest Coverage Ratio stood at 20.59 in 2021, then sank by 193.41% to 60.4 in 2022, then sank by 837.99% to 566.55 in 2023, then tumbled by 134.41% to 1328.06 in 2024, then soared by 55.77% to 587.39 in 2025.
- Business Quant data shows ENSC's Interest Coverage Ratio at 587.39 in Q3 2025, 553.96 in Q2 2025, and 510.25 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 2.82 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.08 |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.42 |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 76.86 |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -587.39 |
| Jun 30, 2025 | -553.96 |
| Mar 31, 2025 | -510.25 |
| Dec 31, 2024 | -1,328.06 |
| Sep 30, 2024 | 158.69 |
| Jun 30, 2024 | -70.94 |
| Mar 31, 2024 | -1.48 |
| Dec 31, 2023 | -566.55 |
| Sep 30, 2023 | -353.94 |
| Mar 31, 2023 | -1,710.91 |
| Dec 31, 2022 | -60.40 |
| Sep 30, 2022 | -1,268.43 |
| Jun 30, 2022 | -151.68 |
| Mar 31, 2022 | -319.74 |
| Dec 31, 2021 | -20.59 |
| Sep 30, 2021 | -5.74 |
| Jun 30, 2021 | -0.01 |
| Mar 31, 2021 | -1.51 |
| Dec 31, 2020 | -4.41 |
| Sep 30, 2020 | -1.87 |